Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the appointment of Dr. Jan Skvarka to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry. Dr. Skvarka has a proven track record of leading clinical-stage companies and has successfully transformed Trillium Therapeutics, resulting in a significant acquisition by Pfizer. His expertise is expected to guide Zentalis as it develops its lead candidates, ZN-c3 and ZN-d5, which target various cancers. Zentalis aims to advance its pipeline of innovative cancer therapeutics amidst ongoing industry challenges.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on September 1, 2022, the grant of 125,000 non-qualified stock options to a new employee under the 2022 Employment Inducement Incentive Award Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $27.86, equivalent to the closing price on the grant date. The options will vest over four years. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with a pipeline that includes potential best-in-class candidates.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Kimberly Blackwell will participate in investor conferences. The 2022 Wells Fargo Healthcare Conference is set for September 7, 2022, at 2:35 p.m. ET in Boston, followed by the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:35 a.m. ET in New York City. Webcasts will be available on Zentalis' website.
As a clinical-stage biopharmaceutical firm, Zentalis focuses on small molecule therapies for cancer, with a diverse pipeline that includes potent candidates for various malignancies.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced key corporate developments and financial results for Q2 2022. The company appointed Dr. Kimberly Blackwell as CEO and Dave Johnson as Chairman, enhancing its leadership team. A $25 million equity investment from Pfizer aims to advance ZN-c3's clinical development. Zentalis raised approximately $200.2 million from a recent share offering, extending its cash runway into 2025. As of June 30, 2022, cash and marketable securities totaled $455.2 million, with R&D expenses slightly down to $43.8 million, while general administrative expenses rose to $19.6 million due to increased stock-based compensation.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced that CEO Kimberly Blackwell will speak at the Wedbush PacGrow Healthcare Conference on August 10, 2022, at 10:20 a.m. ET. This panel will focus on targeted oncology strategies. The event will be accessible via a live webcast on the company's website, with an archived version available afterward. Zentalis specializes in small molecule therapeutics aimed at critical cancer pathways and has a diverse pipeline, including treatments like ZN-c3 and ZN-d5.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on August 1, 2022, that its Compensation Committee granted non-qualified stock options for 290,500 shares to new General Counsel Andrea Paul. This grant is part of the 2022 Employment Inducement Incentive Award Plan, aimed at attracting non-employee talent. The options have an exercise price of $28.82, equal to the stock's closing price on the grant date, a 10-year term, and will vest over four years contingent on continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Andrea Paul, J.D., as General Counsel and Corporate Secretary, effective August 1, 2022. With extensive experience in healthcare legal matters, Paul previously served in similar roles at LogicBio Therapeutics and Akebia Therapeutics. Dr. Kimberly Blackwell, CEO, expressed confidence in Paul's ability to navigate complex legal challenges, supporting the company's clinical ambitions. Zentalis focuses on developing small molecule therapeutics targeting cancer pathways and has a pipeline that includes product candidates for various cancer types.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation by CEO Kimberly Blackwell and CFO Melissa Epperly in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 a.m. ET. This event will be available via live webcast on the company’s website, with an archived version to follow. Zentalis is a clinical-stage biopharmaceutical company focusing on oncology therapeutics, developing candidates targeting pivotal cancer pathways, including ZN-c3 and ZN-d5. For more details, visit www.zentalis.com.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced the promotion of Cam Gallagher to President. Gallagher, a co-founder and former Executive Director, brings 30 years of experience in life sciences. He will lead corporate and business development initiatives under CEO Dr. Kimberly Blackwell's leadership. Gallagher expressed confidence in Zentalis' potential, especially regarding lead assets ZN-c3 and ZN-d5, as the company advances its clinical strategy. Zentalis focuses on developing small molecule therapeutics targeting biological pathways in cancer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has successfully completed an underwritten offering of 10,330,000 shares at $19.38 per share, raising approximately $200.2 million. The proceeds will support ongoing and planned clinical trials for its innovative oncology candidates, including ZN-c3 and ZN-d5, as well as general corporate purposes. The offering was managed by prominent financial institutions including Morgan Stanley and Jefferies. This financing aims to bolster Zentalis's pipeline in the competitive oncology market.